Additionally, Metrnl improves diabetic cardiomyopathy and reduces heart cell damage by inhibiting cGAS/STING signaling through autophagy (Lu et al. 2023a), but also attenuates adriamycin-induced cardiotoxicity via activation of the cAMP/PKA/SIRT1 pathway (Hu et al. 2020). This evidence concerns the gene SIRT1 and diabetic cardiomyopathy.